Missouri is currently home to 1899 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
NCT05626114
Recruiting
This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated. The substudy will evaluate the operational feasibility and scientific interpretability of incorporating AO retinal imaging using the EarlySight Cellularis® Discovery device. Participants who have fulfi... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
08/13/2025
Locations: The Retina Institute, Saint Louis, Missouri
Conditions: Geographic Atrophy
Register for Updates
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578
Recruiting
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Local Institution - 017-820F, Kansas City, Missouri
Conditions: Advanced NSCLC, Metastatic Lung Cancer
Register for Updates
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
NCT05372614
Recruiting
This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors that have spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable), and have changes in a gene called human epidermal growth factor receptor 2 (HER2). Neratinib is in a class of medications called kinase inhibitors. It works by blocking the action of an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Register for Updates
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416
Recruiting
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. In Part 1 and Part 2 of the study, participants in the study will either receive elranatamab (arm A and C) as an injection under the skin at the study clinic or lenalidomide orally once daily at home (arm B). Participation in the study will be app... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: American Oncology Partners, P.A. Dba MidAmerica Cancer Care, Kansas City, Missouri
Conditions: Multiple Myeloma
Register for Updates
MiSight 1 Day Post-Approval Study for Effectiveness and Visual Symptoms
NCT05285553
Recruiting
The purpose of this post-approval study is to confirm the effectiveness of the MiSight 1 Day lens in clinical practices within the US and to assess the stability of the myopia reduction over one-year post-treatment.
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
08/13/2025
Locations: Vision Source EyeCare, Kansas City, Missouri
Conditions: Myopia
Register for Updates
MiSight 1 Day Safety Post-Approval Study
NCT05285527
Recruiting
The purpose of this post-approval study is to confirm the safety of daily disposable soft contact lens wear among the intended patient population for the MiSight 1 Day lens in the US.
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
08/13/2025
Locations: Missouri Eye Consultants - California, California, Missouri
Conditions: Myopia
Register for Updates
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398
Recruiting
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \<18 years with episodic migraine.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/13/2025
Locations: University of Missouri - Investigational Pharmacy, Columbia, Missouri
Conditions: Migraine
Register for Updates
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
NCT05134012
Recruiting
This a Phase 3, prospective, open-label, multicenter study of \[15-O\]-H2O injection for PET imaging of subjects with suspected CAD. Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study at approximately 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled to account for an estimated 15% drop-out rate. Screening assessments will occur prior to enrollment to confirm eligibility. All participants wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: Coronary Artery Disease
Register for Updates
A Study of AMG 193 in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)
NCT05094336
Recruiting
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of AMG 193 in adult participants with metastatic or locally advanced MTAP-nul... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/13/2025
Locations: Washington University, Saint Louis, Missouri
Conditions: Advanced MTAP-null Solid Tumors
Register for Updates
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141
Recruiting
The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of migraine in children and adolescents (≥ 6 to \< 18 years of age).
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/13/2025
Locations: Sharlin Health Neuroscience Research Center, Ozark, Missouri
Conditions: Acute Treatment of Migraine
Register for Updates
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242
Recruiting
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
08/13/2025
Locations: Sharlin Health Neuroscience Research Center, Ozark, Missouri
Conditions: Pediatric Migraine
Register for Updates
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Subtudy to Evaluate the Safety of Re-Implanting the PDS With Ranibizumab in Participants With DME
NCT04108156
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of the PDS with Ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W). The substudy will evaluate safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in participants with DME who were previously enrolled in the main Study, GR40550. Up to 100 participants from the main study will b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2025
Locations: Pepose Vision Institute, Chesterfield, Missouri
Conditions: Diabetic Macular Edema
Register for Updates